News Focus
News Focus
icon url

TastyTheElf

01/14/26 11:05 AM

#444619 RE: Tseven #444615

That is true about the bear market in small biotech. Last year there was a near complete exodus of VCs putting money into the sector.

It set off a slew of bankruptcies, and as you said, those who still had cash were trading at a discount to it.

Amarin isn't really a "biotech" any more -- it's not developing anything, it's just managing the runoff of an approved drug. But still.